Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel S Mulligan

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|December 15, 2010
Quantitative approaches to amyloid imagingVictor L Villemagne, Graeme O'Keefe, Rachel S Mulligan, et al.
Neuroimage|July 26, 2003
Analysis of D2 dopamine receptor occupancy with quantitative SPET using the high-affinity ligand [123I]epidepride: resolving conflicting findingsKjell Erlandsson, Rodrigo A Bressan, Rachel S Mulligan, et al.
Journal of Clinical Psychopharmacology|January 25, 2003
Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET studyRodrigo A Bressan, Kjell Erlandsson, Hugh M Jones, et al.
Biological Psychiatry|July 5, 2005
Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivoRodrigo A Bressan, Kjell Erlandsson, James M Stone, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 12, 2017
Management Impact of Imaging Brain Vesicular Monoamine Transporter Type 2 in Clinically Uncertain Parkinsonian Syndrome with <sup>18</sup>F-AV133 and PETPaschal K Alexander, Yenni Lie, Gareth Jones, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 26, 2016
Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid ScaleChristopher C Rowe, Gareth Jones, Vincent Doré, et al.
Annals of the New York Academy of Sciences|December 20, 2003
Evaluation of NMDA receptors in vivo in schizophrenic patients with [123I]CNS 1261 and SPET: preliminary findingsRodrigo A Bressan, Kjell Erlandsson, Rachel S Mulligan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 12, 2013
Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementiaChristopher C Rowe, Svetlana Pejoska, Rachel S Mulligan, et al.
BMJ Open|November 18, 2018
Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patientsSan San Xu, Paschal K Alexander, Yenni Lie, et al.
Nuclear Medicine and Biology|May 28, 2003
Kinetic modelling of [123I]CNS 1261--a potential SPET tracer for the NMDA receptorKjell Erlandsson, Rodrigo A Bressan, Rachel S Mulligan, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Methods in Molecular Biology (Clifton, N.J.)|December 15, 2010
Quantitative approaches to amyloid imagingVictor L Villemagne, Graeme O'Keefe, Rachel S Mulligan, et al.
Neuroimage|July 26, 2003
Analysis of D2 dopamine receptor occupancy with quantitative SPET using the high-affinity ligand [123I]epidepride: resolving conflicting findingsKjell Erlandsson, Rodrigo A Bressan, Rachel S Mulligan, et al.
Journal of Clinical Psychopharmacology|January 25, 2003
Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET studyRodrigo A Bressan, Kjell Erlandsson, Hugh M Jones, et al.
Biological Psychiatry|July 5, 2005
Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivoRodrigo A Bressan, Kjell Erlandsson, James M Stone, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 12, 2017
Management Impact of Imaging Brain Vesicular Monoamine Transporter Type 2 in Clinically Uncertain Parkinsonian Syndrome with <sup>18</sup>F-AV133 and PETPaschal K Alexander, Yenni Lie, Gareth Jones, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 26, 2016
Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid ScaleChristopher C Rowe, Gareth Jones, Vincent Doré, et al.
Annals of the New York Academy of Sciences|December 20, 2003
Evaluation of NMDA receptors in vivo in schizophrenic patients with [123I]CNS 1261 and SPET: preliminary findingsRodrigo A Bressan, Kjell Erlandsson, Rachel S Mulligan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 12, 2013
Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementiaChristopher C Rowe, Svetlana Pejoska, Rachel S Mulligan, et al.
BMJ Open|November 18, 2018
Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patientsSan San Xu, Paschal K Alexander, Yenni Lie, et al.
Nuclear Medicine and Biology|May 28, 2003
Kinetic modelling of [123I]CNS 1261--a potential SPET tracer for the NMDA receptorKjell Erlandsson, Rodrigo A Bressan, Rachel S Mulligan, et al.
Pageof 4